hrp0094p2-91 | Bone, growth plate and mineral metabolism | ESPE2021

Two-year experience of burosumab therapy in pediatric XLH patients in Saudi Arabia

AlJuraibah Fahad , Aldubayee Mohamed , Alsagheer Afaf , Shaikh Adnan Al ,

Background: X-linked hypophosphatemia (XLH) is a rare, often debilitating genetic disorder caused by mutations in the phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) that is characterized by excess fibroblast growth factor 23 (FGF23), hypophosphatemia, skeletal deformities, and growth impairment.1,2 Conventional therapy with the combination of phosphate and active vitamin D is associated with poor treatment adh...